Long-Term Survival of Cancer Patients Following COVID-19 Infection: Prognostic Value of Inflammatory Indices and Vaccination Status COVID-19 Enfeksiyonu Sonrası Kanser Hastalarında Uzun Süreli Sağkalım: İnflamatuar İndekslerin Ve Aşılama Durumunun Prognostik Değeri

Creative Commons License

Sali S., Ötegeçeli M. A., Özalp Ş., ŞAHİN A. B., OCAK B., SALİ M., ...Daha Fazla

Journal of Uludag University Medical Faculty, cilt.52, 2026 (Scopus)

Özet

The survival outcomes of cancer patients exposed to Coronavirus Disease 2019 (COVID-19), the duration required to resume oncological treatment, and the subsequent course of their malignancy remain areas with limited data. This retrospective study evaluated 128 cancer patients hospitalized for COVID-19 treatment between April 2020 and October 2023. Of the cohort, 39.8% were women and 60.2% were men. Findings revealed that patients with metastatic lung involvement faced a 3.34-fold increased risk of death during the acute infection. In the post-COVID survival cohort, multivariate analysis indicated that younger age, higher hemoglobin levels, higher systemic inflammatory index, lower pan-immune inflammation value, and absence of active cancer were associated with longer survival. Additionally, vaccine-related survival differences were observed; however, these findings should be interpreted cautiously as they likely reflect confounding factors such as prioritizing high-risk patients for certain vaccine types rather than a direct causal relationship. Notably, while treatment delays were common among patients with disease progression, these delays did not result in a statistically significant difference in overall survival during the long-term follow-up.